FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)

01:00 EDT 11 Oct 2013 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
CIU is a skin condition characterized by red, swollen, itchy hives Currently, H1-antihistamines are the only approved therapy for patients suffering from CIU, also known as chronic spontaneous urticar...

Other Sources for this Article

Genentech
Media Contact:
Chris Vancheri, 650-467-6800
or
Investor Contacts:
Thomas Kudsk Larsen, 650-467-2016
Karl Mahler, 011 41 61 687 8503

NEXT ARTICLE

More From BioPortfolio on "FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)"

Search BioPortfolio:
Advertisement

Relevant Topics

Dermatology
Latest News Clinical Trials Research Drugs Reports Corporate
Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers a range of diseases including skin allergies, alopecia, Behcet'...

Allergies
Latest News Clinical Trials Research Drugs Reports Corporate
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Advertisement

Searches Linking to this Story